The ongoing mission of the Michigan Cancer Research Consortium (MCRC) CCOP has been to improve the oncologic health of the communities it serves by assuring access to and participation in state-of-the-art clinical trials and cancer prevention and control activities while contributing to knowledge development in the field of oncology care. Over the past 20 years, the MCRC represents a proven resource with significant potential to serve the objectives of the National Cancer Institute's NCORP program. First funded in 1994 as a single component CCOP, the MCRC is now comprised of thirteen health systems and 150+ oncology investigators from 50+ practices in three states. MCRC has registered over 7,700 patients to trials. Annual accrual approaches 400+ credits and the MCRC's organizational efficiencies are among the best models in the country. Additional value is added as the primary awardee and lead institution of the MCRC, Saint Joseph Mercy Health System, actively contributed to the National Community Cancer Centers Program (NCCCP) from 2010-2012. Participation provided MCRC with experience and growth in key areas of importance to the NCORP program by increasing access to care, participating in Cancer Care Delivery Research, and improving quality of care across the continuum and participation in biospecimen banking. MCRC has already sought resources and experiences to assure development of infrastructure to master Cancer Care Delivery Research. Our experience positions us for success given our proven track record in clinical trials and competency and strategic partnerships to be active members of the NCTN's Cancer Care Delivery Research program. This grant proposal encompasses and articulates a vision that the MCRC will be a productive member of the newly developed NCORP program.

Public Health Relevance

The NCORP Community Sites will accrue patients/participants to NCI-approved cancer clinical trials and cancer care delivery research (CCDR). The MCRC, which is the largest community research consortium in the state of Michigan serving the adult populations, has successfully incorporated CCDR and has capacity to successfully assist the NCI in meeting the goals of the NCORP in a multi-state initiative.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189971-04
Application #
9322009
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Lee, Cecilia H
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Saint Joseph Mercy Health System
Department
Type
DUNS #
807606249
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527

Showing the most recent 10 out of 19 publications